These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33474678)

  • 1. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.
    Wu S; Deng C; Zhang C; Xiong J; Gu X; Wang Z; Tu J; Xie J
    Clin Transl Oncol; 2021 Aug; 23(8):1549-1560. PubMed ID: 33474678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant cucurmosin-based immunotoxin targeting HER-2 with potent in vitro anti-cancer cytotoxicity.
    Xiong J; Zhang C; Wu S; Gu X; Cai Y; Xu C; Chen Z; Sun J; Wu X; You X; Huang Z; Xie J
    Biochem Biophys Res Commun; 2019 May; 513(1):15-21. PubMed ID: 30917887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
    Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
    Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel cucurmosin-based immunotoxin targeting programmed cell death 1-ligand 1 with high potency against human tumor in vitro and in vivo.
    Zhang C; Xiong J; Lan Y; Wu J; Wang C; Huang Z; Lin J; Xie J
    Cancer Sci; 2020 Sep; 111(9):3184-3194. PubMed ID: 32589330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An epidermal growth factor receptor-targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer.
    Huang M; Park J; Seo J; Ko S; Yang YH; Lee Y; Kim HJ; Lee BS; Lee YS; Ko BJ; Jung ST; Park D; Yoo TH; Kim CH
    FASEB J; 2024 Jul; 38(13):e23759. PubMed ID: 38949635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
    Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
    J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel EGFR‑bispecific recombinant immunotoxin based on cucurmosin shows potent anti‑tumor efficiency in vitro.
    Zhang C; Cai Y; Dai X; Wu J; Lan Y; Zhang H; Lu M; Liu J; Xie J
    Oncol Rep; 2021 Feb; 45(2):493-500. PubMed ID: 33416157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
    Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
    Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells.
    Landi N; Ciaramella V; Ragucci S; Chambery A; Ciardiello F; Pedone PV; Troiani T; Di Maro A
    Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
    Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
    Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
    Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models.
    Miyamoto Y; Muguruma N; Fujimoto S; Okada Y; Kida Y; Nakamura F; Tanaka K; Nakagawa T; Kitamura S; Okamoto K; Miyamoto H; Sato Y; Takayama T
    Cancer Sci; 2019 Jun; 110(6):1921-1930. PubMed ID: 30973663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
    Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
    Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.
    Kim N; Cho D; Kim H; Kim S; Cha YJ; Greulich H; Bass A; Cho HS; Cho J
    Int J Cancer; 2020 Apr; 146(8):2194-2200. PubMed ID: 31290142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
    Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brexpiprazole Prevents the Malignant Progression of Human Colorectal Cancer Cells and Increases Its Sensitivity to EGFR Inhibition.
    Long X; Liu X; Xia W; Liu L; Chen W
    Front Biosci (Landmark Ed); 2024 May; 29(5):174. PubMed ID: 38812296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
    Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
    Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.